Affymetrix to Webcast Presentation at UBS Global Life Sciences Conference
20 September 2006 - 11:00PM
Business Wire
Affymetrix, Inc. (Nasdaq:AFFX) today announced it will webcast its
presentation from the UBS Global Life Sciences Conference in New
York City. Greg Schiffman, Executive Vice President and Chief
Financial Officer, will provide a company update and financial
details on the previously announced corporate restructuring at 1:30
p.m. ET on Wednesday, September 27th. An audio transmission of the
presentation will be available live and by replay. To access both
the live and archived webcast, please go to www.affymetrix.com and
click on the "Investors" link. The archived replay will be
available for 30 days. About Affymetrix Affymetrix scientists
invented the world's first high-density microarray in 1989 and
began selling the first commercial microarray in 1994. Since then,
Affymetrix GeneChip(R) technology has become the industry standard
in molecular biology research. Affymetrix technology is used by the
world's top pharmaceutical, diagnostic and biotechnology companies
as well as leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks of the
Company's ability to achieve and sustain higher levels of revenue,
higher gross margins, reduced operating expenses; uncertainties
relating to technological approaches, manufacturing, product
development; personnel retention; uncertainties related to cost and
pricing of Affymetrix products; dependence on collaborative
partners; uncertainties relating to sole source suppliers;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix' Form 10-K/A for the
year ended December 31, 2005, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix'
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Affymetrix, Inc. (NASDAQ): 0 recent articles
More Affymetrix, Inc. News Articles